Browsed by
Tag: Synthetic

Dotmatics Introduces Blueprint to Provide Self-service Data Analysis for Medicinal and Synthetic Chemists

Dotmatics Introduces Blueprint to Provide Self-service Data Analysis for Medicinal and Synthetic Chemists

  • Self-service scientific data visualization and analytics application designed to empower chemists working on small molecule discovery projects

  • Blueprint provides guided wizard-driven analytics for bench scientists to analyze project data, design compounds and make informed decisions, faster

  • Web-based solution fully integrated into existing Dotmatics applications to provide a seamless end-to-end chemistry design workflow

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. The introduction of Blueprint broadens the existing Dotmatics suite for chemistry design workflows, adding to the Company’s comprehensive selection of web-based solutions.

As drug discovery research continues to become increasingly data-driven, the limited availability of specialist data scientists and computational chemists, in addition to the complexity and restrictions of legacy cheminformatics tools, have become a bottleneck for research organizations. There is now a high demand for self-servicing tools, specifically aimed at non-data-specialists, to increase workflow efficiency and staff productivity. Designed to support project scientists with minimal training, Blueprint employs guided wizard-driven analytics to enable users to analyze structure-activity data, design compounds and rapidly make the best-informed decisions with real-time data. The application also facilitates collaboration in-house or with external partners. Blueprint seamlessly integrates into the existing Dotmatics suite of search and experiment capture capabilities which support the full drug discovery cycle, from compound design to analysis. Within a single workflow, scientists can assemble project data across multiple third-party systems; explore molecular data sets; design new molecular series or libraries; and automatically generate experiments in their electronic lab notebook.

Dr Stephen Gallagher, Co-Founder and Chief Executive Officer Dotmatics, commented:Blueprint is a key new component of the Dotmatics solution

Read the rest